Brookline Capital Markets analyst Kemp Dolliver downgraded Rein Therapeutics (NASDAQ: RNTX) from Buy to Hold.The analyst comments: "RNTX’s Q2 update ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE